Surgical outcome following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. by Yamini Chitra, V
SURGICAL OUTCOME FOLLOWING NEOADJUVANT 
CHEMORADIOTHERAPY FOR LOCALLY ADVANCED RECTAL 
CANCER
Dissertation submitted in partial fulfillment of the requirements for the 
degree of
M.Ch. SURGICAL GASTROENTEROLOGY
Batch – VI
MADRAS MEDICAL COLLEGE
CHENNAI
AUGUST 2008
CERTIFICATE
Certified  that  this  dissertation  titled   “SURGICAL  OUTCOME  FOLLOWING 
NEOADJUVANT  CHEMORADIOTHERAPY  FOR  LOCALLY  ADVANCED  RECTAL 
CANCER” is the bonafide record work done by  Dr. Yamini Chitra. V. during the 
period 2005-08, done under my guidance and supervision and is submitted in partial 
fulfillment of the requirement for the M.Ch. (Branch – VI) Surgical Gastroenterology 
& Proctology,  of  The  Tamil  Nadu  Dr.  M.G.R.  Medical  University,  August  2008 
examination.
The DEAN, 
Madras Medical College, 
Chennai – 3.        
Prof.SRIKUMARI  DAMODARAM,  M.S., 
M.Ch., 
Prof.  & HOD,   
Dept. of Surgical Gastroenterology,
Madras Medical College, Chennai – 3.
Date & Seal
ACKNOWLEDGMENTS
I wish to thank the Dean, Madras Medical College, Chennai for having permitted to carry out 
this study at Madras Medical College Hospital.
I am greatly indebted to my Professor and Head of Department Prof. Srikumari Damodaram 
M.S., M.Ch, for her guidance and encouragement throughout the period of my study.
I express my gratitude for the guidance given by the Assistant Professors Dr.O.L.Naganath 
Babu,  Dr.T.Selvaraj  and  Dr.P.Raghumani  of  the  Department  of  Surgical  Gastroenterology for  the 
completion of the study.
I acknowledge the co-operation and help rendered by my fellow post-graduates. 
I thank my family members who stood by me in successfully completing this study.
I thank all the patients who cooperated with me in carrying out this study,  in spite of their 
illness. This work would be complete and successful, if it had contributed, even in the smallest possible 
way, to alleviate their suffering.
CONTENTS
1. Introduction 1
2. Aim 2
3. Review of literature    3
4. Materials and Methods 27
5. Results 32
6. Discussion 44
7. Conclusion 64
8. References 65
9. Appendix
1. Proforma 70
2. Master Chart 67
Introduction
           The potential for curative resection is the most important component of the multimodality 
management of rectal cancer. In locally advanced rectal cancer lymph node involvement and 
positive resection margins are common, leading to local recurrence and metastatic disease. 
Postoperative chemoradiotherapy significantly improves both local control and overall survival. 
Several studies have shown that preoperative chemoradiotherapy has increased local control rates, 
sphincter saving procedures and resectability. This study evaluates the potential benefits and outcome 
following neoadjuvant chemoradiotherapy for locally advanced operable rectal cancer. 
Aim
                The aim of the study is to analyse the surgical outcome following neoadjuvant 
chemoradiotherapy in patients with locally advanced  operable rectal cancer i.e. T 3, T 4, node positive 
tumour. Its main aim is to analyse whether
1. It is beneficial to the patient or not.
2.  The primary end points analysed are the downsizing of tumour, downstaging of the tumour, 
sphincter saving rates, toxicity of chemoradiotherapy, patient compliance for the regimen. 
3. Secondary end points analysed are the incidence of local recurrence, distant metastasis. The 
incidence of peroperative complications and postoperative complications are also analysed.
Review of Literature
               
                     The main problem in treatment of locally advanced cancer rectum is that many are 
unresectable or even if resected have a high incidence of local recurrence. Lack of improvement in the 
surgical results in three decades prompted many investigators to seek different radiotherapeutic 
approaches in conjunction with surgery. In the1960s and 1970s various American and European 
clinicians reported favorable, but sometimes conflicting, results on this subject. These results 
nevertheless gave the impression that preoperative radiotherapy had a place in the management of 
patients with potentially operable rectal cancer. In 1969, Moertel and Reitemeie P1 showed that 
combined radiotherapy and 5- fluorouracil gave significantly better subjective as well as objective 
results in the management of advanced gastrointestinal malignancies.
                     Age impacts colorectal cancer incidence more than any other demographic factor. The 
incidence of sporadic colorectal cancer increases dramatically above the age of 45 or 50 years for all 
groups. Cancer incidence and mortality rates have been higher in economically advantaged countries. 
This may be related to consumption of a high-fat and high-red-meat diet, lack of physical activity with 
resulting obesity, and variations in mortality causes over a longitudinal period of time.
Mode of spread of rectal cancer      
            
                Different treatment modalities are available due to various routes of spread, namely direct, 
lymphatic, venous, transcoelomic or by implantation. Direct spread of rectal tumour can occur in 
longditudinal, transverse directions or proximally or distally. Williams et al in 1983 has shown that 
distal intramural spread greater than one cm is uncommon and when it does occur patients have 
tumours which are incurable with the available treatment options. There is no substantial evidence to 
show that a distal resection margin of five cm reduces the chance of local reccurence.
                Radial spread from a cancer located on the posterior wall of the rectum may extend through 
the mesorectum and involve the Waldeyer’s fascia. Anterior spread from tumour located below the 
peritoneal reflection in a male may involve prostrate, seminal vesicle or bladder. Williams et al have 
shown that leaving residual disease in the pelvis is the main cause for local recurrence.
 Lymphatic Spread
             Rectal tumour can spread in upward, lateral and downward directions. Distal lymphatic spread 
is rare and occurs when the upward route is extensively involved. Wide lateral spread occurs in extra 
peritoneal tumours but is uncommon in tumours above the peritoneal reflection. Discontinuous spread 
also occurs in about 30 % of cases.
Blood spread can occur to liver, lungs, kidneys, bones and ovary. Greater the incidence and 
degree of venous invasion worse is the prognosis. Intramural and extra mural veins can be involved and 
greater the extramural involvement, worse the prognosis.
Local Recurrence in Rectal Cancer
 Role of Total Mesorectal excision 
        Total mesorectal excision is precise sharp dissection around the integral mesentry of the hind 
gut which envelopes the entire hindgut. By performing this manouvre, all micro metastatic tissue which 
lie in the mesorectum will be removed enbloc with the rectum and the tumour. The concept of TME 
was introduced by 
TME with intact Fascia Propria 
Pelvic cavity post TME
Heald in 1982 2 .Arbman et al3  in 1996 compared their results for rectal cancer after adopting the 
technique of TME with results before using it. They found significant reduction in local recurrence 
rates (p<0.03) and an increase in crude survival (p <0.03) at four years in patients who had undergone 
total mesorectal excision.
         So total mesorectal excision should be done for tumours of mid and lower rectum. In upper 
rectal tumours mesorectum should be removed at least five cm below the palpable edge of the tumour. 
However such a manouvre is likely to increase the risk of anastamotic leakage because of the danger of 
rendering the anorectal stump ischaemic. Thus a covering stoma is necessary for all patients 
undergoing a total mesorectal excision except in patients undergoing abdominoperineal excision of 
rectum. 
                     
Role of Lateral pelvic lymph node dissection
    In rectal cancers,lymphatic spread not only occurs upwards to the mesenteric nodes along the 
superior rectal and inferior mesenteric vessels, but also laterally to the hypogastric,obturator and nodes 
along iliac vessels. The incidence ranges from 8.6 to 17.3 % 4.  The local recurrence rate is high and 
survival is poor in these patients compared with those having positive mesorectal lymph nodes. But 
extended dissection impairs urinary and  male sexual function, resulting in poor 
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quality of life, as the pelvic autonomic nerves are sacrificed during lateral lymph node dissection. 
Various autonomic nerve preservation procedures have been developed resulting in improved urinary 
function. Morita5  et al in 2003 has shown that overall recurrence rate was only 6.3 % and five year 
survival was 47 %. But even after lateral lymph node dissection, the prognosis of patients with pelvic 
autonomic plexus involvement was unfavourable.
       Jin C Kim et al 6  has compared the outcome between adjuvant postoperative 
chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision for 
rectal tumours  upto 15 cm from anal verge. There was no difference in overall survival (78 % vs 
73.9% ) or disease free survival(67.3% vs 68.6 %). But the locoregional reccurrence rate was 2.2 fold 
higher in the lateral lymph node dissection group than postoperative chemoradiotherapy group(16.7 % 
vs7.5 5 ,p = 0.044 ). The addition of lateral lymph node dissection to total mesorectal excision 
prolonged time in surgery by 90 to 120 minutes and increased the transfusion requirement by more than 
50 %. So the authors concluded that even after lateral lymphnode dissection, postoperative 
chemoradiotherapy was needed to decrease local recurrence. Hence lateral lymphnode dissection is of 
no added benefit to the patient.
              There is a high incidence of locoregional and distal recurrence in locally advanced rectal 
cancers following only surgical treatment. Various treatment modalities in form of neoadjuvant 
radiotherapy, adjuvant radiotherapy, adjuvant chemotherapy, adjuvant chemoradiotherapy has been 
tried.
             Patients with rectal cancer can be divided into three main groups. Most patients have resectable 
cancers. Patients in the next category have borderline resectable disease, that is breached 
circumferential margins as predicted by imaging studies. Finally, there are patients with fixed 
unresectable cancers, for whom surgery is not possible without leaving tumor within the pelvis. This 
group may, after chemoradiotherapy,  become respectable.
            .In clinically resectable cancers, residual microscopic disease after surgery can persist either at 
or beyond the surgical resection margins, within lymph nodes, or in distant metastatic sites. In locally 
advanced rectal cancer (LARC),  lymph node involvement and positive resection margins are common, 
leading to local recurrence and metastatic disease. Both radiotherapy and chemotherapy have been 
advocated as adjuvant strategies  to eradicate cells at the margins or in discontinuous areas of tumor 
within the pelvis, in nodes, or in distant metastatic sites to improve both local control and also overall 
survival (OS). In borderline unresectable rectal cancers, a high risk for local recurrence and poor 
survival have been reported with preoperative radiotherapy alone .This finding illustrates the need for 
combining therapies that integrate concurrent chemotherapy, radiotherapy, and surgery. Chemotherapy 
may, as a component of chemoradiotherapy, both act as a radiosensitizing agent and also potentially 
eradicate distant micrometastases. This strategy has been investigated with different agents in a number 
of phase I/II and III trials of preoperative neoadjuvant chemoradiotherapy.
Role of preoperative radiotherapy
              On administering preoperative radiotherapy the size of primary tumour and the number of 
nodes involved are reduced. The extent of pathological down grading of tumour achieved  varies with 
the dose of radiation used. This is proved by MRC trial  in 1984 were a statistically significant 
reduction  of 30 %  of number of nodes involved and negative nodes after a fractionated irradiation of 
20 Gy, but no difference was observed between the group which received a single dose of 5 Gy and the 
control group.
      Preoperative radiotherapy also reduces local recurrence. It helps reduce the size and extent of 
local spread and makes a locally advanced tumour operable incertain cases. But it is associated with 
high toxicity and abdominal and perineal wound healing is affected. Most of the studies have not 
shown any improvement in overall survival compared to surgery alone. Preoperative radiotherapy with 
the aim of  improving local control has been studied extensively. 
         In 1974 Stearns.et al 7  reported on the results in the trial of preoperative radiotherapy, in 
Memorial Sloan Kettering Cancer Centre in New York. Patients were randomized to receive 20 Gy of 
preoperative radiotherapy or surgery only. No improvement in overall survival or local recurrence was 
noted
.
    The Veterans administration Oncology Group (VASOG ) had 20 Gy given preopatively for two 
weeks followed by surgery. Additional 5 Gy was given if tumour was within five cm of anal verge. 
This study showed that there was reduction in number of nodes involved by the tumour after 
irradiation,down grading of the tumour.  There was reduction in local recurrence after radiotherapy in a 
subgroup who underwent post mortem.
             The Swedish Rectal cancer group8  has shown that short course of radiotherapy of twenty five 
gray in five fractions over five days followed by surgery in seven days had decreased local reccurrence 
and improved overall survival(58 % vs  48 % p <0.004).   
                   
Role of Radiotherapy in unresectable rectal cancer 
                      For those patients in whom CT suggests that the tumour is unresectable, preoperative 
radiotherapy either alone or ideally in combination with chemotherapy, is recommended. Preoperative 
radiotherapy without chemotherapy for such locally advanced tumors using doses of 45–50 Gy  was 
reported to be capable of downstaging 79% of patients, which resulted in high resection rates being 
achieved.  Despite complete resection, the 5-year survival rate was only 18%, and these patients 
continued to have a high risk for local failure. Patients who remain unresectable after radiotherapy have 
an even poorer overall median survival duration of only 8–10 months.
Unresectable Rectal Cancer: Randomized Trials of Chemoradiotherapy versus 
Radiotherapy Alone
                      In a single small phase III  randomized study 9, only 70 patients with fixed inoperable 
rectal cancer were treated. The chemoradiotherapy delivered an alternating hyperfractionated  split-
course regimen to a total dose of 40 Gy over 8 weeks in combination with methotrexate, 5-fluorouracil 
and folinic acid. The trial established an advantage in terms of resectability and local control for the 
chemoradiotherapy arm.
                      The local recurrence-free survival rates at 5 years were 35% versus 66% (p.03) and the 5-
year survival rates were 18% versus 29% (nonsignificant) for radiotherapy versus chemoradiotherapy, 
respectively. These data lend support to the view that chemoradiotherapy is more effective than 
radiotherapy .
                      However, intensification of the chemoradiotherapy component for patients with T1N0 or 
T2N0 rectal cancer may achieve a higher pathological complete response  without a longer overall 
survival. If very low levels of local recurrence is achieved in this group of patients, the risk for 
metastatic disease will almost certainly predominate.
 
Facilitating Sphincter-Sparing Procedures
                     The low  rectal cancers (3–6 cm from the anal verge) and bulky anterior tumors in obese 
men with a narrow pelvis render surgery technically demanding if sphincter-sparing surgery (SPSS) is 
the aim. Long course chemoradiotherapy followed by a planned delay prior to surgery, may result in 
shrinkage back from the distal margin, and enable sphincter-sparing surgery.
                 Impressive results appear to have been achieved in phase II studies with chemoradiotherapy 
and long term follow-up has confirmed an excellent outcome if marked shrinkage of the distal tumor 
margin is demonstrated 10. Subset analysis of randomized trials  suggests that preoperative CRT offers a 
10% 11 or even a 20%12  higher chance overall of achieving sphincter-sparing surgery.
                 Whether a surgeon attempts sphincter-sparing surgery depends on many factors, including 
tumor size, location, and accessibility, surgical experience and training, and the individual’s philosophy 
regarding risk. A randomized trial investigating short course radiotherapy against preoperative 
chemoradiotherapy with the endpoint of sphincter-sparing surgery showed no difference13,  surgeons 
did not change their initial decision.  
Preoperative chemoradiotherapy versus Postoperative chemoradiotherapy in 
Resectable Rectal Cancer
A common randomized trial design compares preoperative chemoradiotherapy with 
postoperative chemoradiotherapy.  There are three trials in this setting - the National Surgical Adjuvant 
Breast and Bowel Project  (NSABP) R03, the Intergroup trial INT-0147, and the German 
CAO/ARO/AIO-94 trial.
National Surgical Adjuvant Breast and Bowel Project Protocol             R-0314
                
       It was designed to determine the worth of preoperative chemotherapy and radiation therapy in 
the management of operable rectal cancer. Patients with primary operable rectal cancer were 
randomized to receive multimodality therapy preoperatively  or after curative surgery . All patients 
received seven cycles of 5-fluorouracil (FU)/leucovorin (LV) chemotherapy. The preoperative arm 
(Group 1) received the first three cycles of chemotherapy and all radiation therapy (5,040 cGy) before 
surgery, and four cycles of chemotherapy post operatively. The postoperative arm (Group 2) received 
all radiation and chemotherapy after surgery. 5- Fluorouracil and leucovorin chemotherapy was given 
during the first and fifth week of radiation therapy.          
                 Primary study end points included disease-free survival and overall survival. Secondary end 
points included local recurrence, primary tumor response to combination therapy, tumor downstaging, 
and sphincter preservation. Overall treatment-related toxicity was similar in both groups.  No patient 
was deemed inoperable because of progressive local disease.  The use of protective colostomy in 
patients undergoing sphincter-sparing surgery and the development of perioperative complications in 
all surgical patients were similar in both groups. There was evidence of tumor downstaging in 
evaluable patients undergoing preoperative therapy, with 8 percent of Group 1 patients having had a 
pathologic complete response. 
               The authors concluded that the preoperative chemotherapy and radiation therapy regimen 
used were safe and tolerable as standard postoperative treatment.
 There was a trend to tumor downstaging and sphincter preservation in the preoperative arm. This  trial 
was closed prematurely due to poor accrual after randomizing only 267 patients.
Intergroup trial INT-014715
     The Intergroup INT-0147 trial also closed early because of poor accrual, after randomizing only 
53 patients. The planned RT dose was 50.4 Gy.
The German CAO/ARO/AIO-94 Trial 12
           The German CAO/ARO/AIO-94 study was initiated in 1995 to investigate preoperative 5-FU–
based chemoradiotherapy versus postoperative combined-modality treatment for stage II/III resectable 
rectal cancer. The primary endpoints were overall survival and disease free survival and locoregional 
and distant control. The secondary endpoints included the rates of curative (R0) resections, sphincter-
sparing surgery, toxicity, and surgical complications. Results show no greater surgical morbidity for 
chemoradiotherapy 12.
              The locoregional failure rate was lower with preoperative chemoradiotherapy -6%, compared 
with 13% for the postoperative arm. However, neither the disease free survival nor overall survival rate 
was greater in the preoperative arm. On subset analysis, a slightly higher sphincter-sparing surgery rate 
was noted for those patients in whom the surgeon initially felt that an abdominoperineal excision of the 
rectum was inevitable. 
              In addition, compliance was low for the postoperative arm, and only 54% received the full 
radiotherapy dose, compared with 9 2 % in the preoperative arm. Both acute and late toxicities 
appeared to be less frequent in the preoperative arm, but it should be noted that a 5.4-Gy radiation 
boost was mandated in the postoperative arm. Patients in the postoperative arm would have received a 
10% higher radiotherapy dose. Radiotherapy dose escalation has rarely been evaluated in rectal cancer 
because of the constraints of acute and late toxicities. 
          The Lyon R 96–0216  study used contact therapy to boost external beam radiotherapy with an 
extra 85 Gy in three fractions. Despite a higher complete clinical response rate and a higher sphincter-
sparing surgery rate, there was no difference in terms of locoregional failure or overall survival at 2 
years. Dose escalation prior to surgical resection seems an illogical strategy to improve local control. If 
surgery can achieve a good quality mesorectal excision, then recurrences are likely to lie outside this 
volume. Consequently, dose escalation of radiotherapy to the primary tumor seems unlikely to achieve 
much more than a higher rate of acute toxicity.
 Preoperative Chemoradiotherapy Versus Radiotherapy Alone
           The second strategy has been to randomize between preoperative neoadjuvant 
chemoradiotherapy and an identical schedule of preoperative radiotherapy alone. One historical and 
two other recent larger studies have used this design.
          In 1984, the European Organization on Research and Treatment of Cancer Gastrointestinal 
Tract Cancer Cooperative Group1  two-arm randomized clinical trial to compare the efficiency of 
preoperative administration of radiotherapy with 5-fluorouracil with radiotherapy alone before radical 
surgery. Two hundred forty-seven eligible patients were admitted from November 1972 through April 
1976. Total tumor dose of 34.5 Gy in 15 fractions of 2.3 Gy each over an overall period of 18 days. 
Patients receiving combined preoperative therapy had intravenous 5-FU injection in the dose of 10 mg 
per kg of body weight (375 mg/m2) during the first four days 4 to 6 hours prior to irradiation. Surgery 
usually followed within 2 weeks after the last irradiation. 
       The overall survival observed in the group treated with preoperative radiotherapy appeared to 
be better than in the group of patients where preoperative combined modality was administered. Five-
year survival was 59% versus 46% with a marginal statistical significance of P=0.06. Although the 
combined modality arm had a higher incidence of side effects and postoperative deaths, it had a greater 
effect than the radiotherapy- alone arm in controlling the disease process, mainly distant metastases to 
the liver with a result bordering on statistical significance (P=0.07). No difference was observed in 
local recurrence. Disease free survival was longer in the combined modality group ,though not 
statistically significant.
                  The incidence of nonmalignant and intercurrent deaths were higher in the combined 
modality group, whereas deaths due to malignancy were higher in the radiotherapy alone group. The 
authors concluded that by observing more stringent selection in disease and patients' criteria, side 
effects and intercurrent deaths can be effectively reduced with further improvement in adjuvant results. 
EORTC 22921 Trial 17
              The EORTC 22921 trial was initiated in 1993 and enrolled 1,011 patients with T3/T4 
resectable rectal cancer over 11 years, with endpoints of overall survival and disease free survival. 
Patients were allocated to the following four arms: arm 1, preop radiotherapy 45 Gy in 5 weeks; arm 2, 
preop radiotherapy plus two 5-day chemotherapy courses ( fluorouracil 350 mg/m 2 /d and leucovorin 
20 mg/m2/d ) in the first and fifth week of radiotherapy; arm 3, preop radiotherapy plus four postop 
chemotherapy courses and arm 4,  preop radiotherapy and chemotherapy plus postoperative 
chemotherapy.
               The study examined the role of the timing and duration of 5-FU–based chemotherapy both in 
combination with preoperative radiotherapy, and in the postoperative adjuvant setting. The trial 
stratified according to T stage, distance to the anal verge, sex, and institution. Total mesorectal excision 
(TME) was only recommended in 1999. Compliance with the preoperative chemotherapy was high, but 
only  42.9% adhered to the postoperative component of chemotherapy. 
               The addition of preoperative  chemotherapy to radiotherapy caused significant down 
sizing(p< 0.001), down staging (p < 0.001 ), had smaller number of  examined  lymph nodes, less 
frequent lymphovascular invasions18. The toxicity was higher in the chemoradiotherapy arm. The 
pathological complete response rate was significantly higher in the chemoradiotherapy arm and it 
appeared to offer a marginal benefit in terms of a higher sphincter-sparing surgery rate ( 55.6 % versus 
52.4 %;  p .05 ). The locoregional failure rates at 5 years were 17% with radiotherapy and 8% with 
chemoradiotherapy. With a median follow-up of 5.4 years, no significant difference was seen in disease 
free survival or overall survival between groups that received sphincter-sparing surgery or radiotherapy 
and those who received further adjuvant chemotherapy postoperatively ( p<.12 ). A major conclusion 
of the study is that if radiotherapy is given, then 5-FU–based chemotherapy,  whether administered 
concurrently with radiotherapy prior to or following surgery, confers a significant advantage in terms 
of local control.
Fédération de Francophone de Cancérologie Digestive -FFCD 9203 Trial 19
              The FFCD 9203 trial19 randomized 762 patients with T3/T4 resectable rectal cancer between 
pre operative radiotherapy and preoperative chemoradiotherapy to a dose of 45 Gy. The same 
chemotherapy regimen as in the EORTC trial (5-FU, 350 mg/m2, and folinic acid) was combined with 
the same dose of radiotherapy (45 Gy in 25 fractions). The primary endpoint was overall survival. In 
contrast to the EORTC study, patients were mandated to receive postoperative adjuvant chemotherapy, 
but compliance was poor and only 70% of patients received it.
           Compliance in the preoperative chemoradiotherapy arm was 93%. The rate of grade 3 or 4 acute 
toxicity was significantly higher in the chemotherapy arm (14.6%, versus 2.7% for radiotherapy alone; 
p.05). Surgical complications, including anastomotic leaks, were similar in the two arms. Similarly to 
the EORTC trial, the pCR rate was higher with chemoradiotherapy, 11.4%, versus 3.6%. There was no 
impact of chemoradiotherapy on sphincter preservation. A lower local recurrence rate was observed, 
8.1%, versus 16.5%. Again, neither disease free survival nor overall survival was significantly different 
in the two groups. A similar number of patients in each arm developed metastatic disease (99 following 
radiotherapy and 107 following chemoradiotherapy).
This trial claims that, from 1999, the majority of patients were treated with TME and the local 
recurrence rate was reduced to 14% for radiotherapy alone and 5% for chemoradiotherapy.
The Polish Trial 13
      The Polish study 13  randomized 316 patients between preoperative long fractionation 
chemoradiotherapy (50.4Gy in 28 daily fractions with 5-FU and folinic acid) and short course 
preoperative radiotherapy. The trial aimed to evaluate whether long course chemoradiotherapy with an 
interval to allow response could facilitate sphincter-sparing surgery when compared with five fractions 
of short-course radiotherapy and immediate surgery. Sphincter-sparing surgery was the main endpoint. 
It is the first time that a long fractionation chemoradiotherapy regimen has been directly compared with 
short course preoperative radiotherapy. The pathological complete response rate was 15% in the 
chemoradiotherapy arm, compared with only 1% in the short course preoperative radiotherapy arm, but 
this did not impact sphincter preservation—61% in the short course preoperative radiotherapy arm 
versus 58% in the chemoradiotherapy arm (p=0.57). Crucially, this trial reported a difference in 
curative resection rates for the two strategies.
          A circumferential resection margin of 1 mm was observed in 4% of patients after 
chemoradiotherapy versus 13% of patients after short course preoperative radiotherapy. The local 
failure rate was 11% after short course preoperative radiotherapy versus 16% in the chemoradiotherapy 
arm, although these are not significantly different. There was no difference in disease free survival and 
overall survival.
          The addition of 5-FU  based chemotherapy to neoadjuvant radiotherapy in the recent European 
randomized trials of rectal cancer led to significantly better tumor downstaging, pathological complete 
response, and local control than with radiotherapy alone, but it does not translate into a benefit in terms 
of longer disease free survival and overall survival, nor a higher chance of sphincter preservation. 
Metastatic disease remains a significant problem. Adding a second drug (mitomycin C, oxaliplatin, or 
irinotecan) results in a higher pathological complete response rate, and could be more effective in 
killing micro metastases, but this strategy has not yet been demonstrated to result in longer disease free 
survival and overall survival.
Material and Methods
This study was conducted in the Department of Surgical Gastroenterology, Madras Medical 
college, Chennai.
Study period
From September 2005 to April 2008 
Eligibility Criteria
            1. All patients with locally advanced operable rectal cancer i.e. T 3, T 4, node positive tumours 
without distant metastasis 
            2. Patients with histologically confirmed adenocarcinoma within 12 cm from anal verge. 
Exclusion Criteria
1. Patients who previously had cancer other than basal cell carcinoma of skin, 
2. Patients who had received chemotherapy or radiotherapy
3. Patients with contraindications to chemoradiotherapy
4. Tumour involving pelvic side walls,upper sacral vetebra, involving upper rectum
5. Distant metastasis .
The study was approved by the medical ethics committee of the hospital.
Preoperative evaluation
                  After obtaining informed written consent, patients were enrolled into the study. 
Locoregional staging was done with contrast enhanced CT of abdomen and pelvis, endorectal 
ultrasound and cystoscopy in cases suspected of bladder invasion. A lymph node metastasis of four or 
greater than four as detected by imaging was staged as N 2 disease. Distant metastasis was excluded by 
contrast enhanced CT of abdomen and pelvis, chest X-ray and if necessary a CT chest. Colonoscopy 
was done to rule out synchronous lesions.
              A basic work up including complete hemogram, renal function tests, liver function tests, and 
cardiac tests like ECG was done to rule out any major illness and to confirm the patient’s fitness for 
surgery.
Treatment
Preoperative external beam radiotherapy was given for a total dose of 45 Gy in 25 fractions of 
180 cGy each, five times per week for total duration of five weeks. It was given as anterior and 
posterior opposed portals using Telecobalt machine of 1.33 meV. The radiotherapy was given to 
include the tumour area and its drainage lymph nodes (pelvic-internal, external iliac, obturator). The 
upper margin of radiotherapy field was L 5-S 1. The lower margin was obturator foramen,1.5 cm below 
lower border of pubic symphysis. The lateral margin was 1 cm lateral to true pelvis at level of mid 
inguinal point. If the tumour extended to anal canal, inguinal nodes were included in the field, laterally 
the radiotherapy field was extended to anterior superior iliac spine.
               The chemotherapeutic agent used was 5 Flurouracil, used as a bolus of 350 mg/m 2 /d for 5 
days, during the first and fifth weeks of radiotherapy along with 20 mg/m2 of leucovorin. 
Postoperatively  5 Flurouracil was given for four cycles (350mg/m2/d,five times weekly once in  four 
weeks) started four weeks after surgery.
Surgery
              Patients were assessed five weeks after surgery regarding the progression of the disease. 
Decision for abdominoperineal excision of rectum , an anterior resection or pelvic exenteration was 
made preoperatively and modified according to the peroperative findings. Total mesorectal excision 
was done in patients according to the standardized technique. All patients who underwent anterior 
resection had a protective ileostomy. Patients with locally advanced unresectable disease underwent 
only colostomy.
               During therapy, patients were monitored weekly for signs of acute toxic effects requiring 
change in dosage or regimen. Acute and long term toxic effects were graded according to the Radiation 
Therapy Oncology Group criteria with respect to acute and late adverse effects of radiotherapy. 
Peroperative and postoperative complications assessed included bleeding, ileus, intestinal fistulas, 
intra-abdominal abscess, perineal wound complications, urinary retention and death.
Follow up
              Patients were followed at three monthly intervals for two years and then at six monthly 
intervals. Evaluations consisted of physical examination, a complete blood count and blood chemical 
analysis, proctoscopy, abdominal ultrasonography, CT of abdomen and chest radiography. Local 
recurrence was to be confirmed histopathologically or by sequential radiological studies to detect 
enlargement of mass. Distal recurrence was confirmed histopathlogically.
         All resected specimens were examined for histological grade, degree of fibrosis, resected 
margin status and nodal status. The primary end points analysed were downsizing of tumour, 
downstaging of the tumour, sphincter saving rates, toxicity of chemoradiotherapy, and patient 
compliance for the regimen. Secondary end points analysed were the incidence of local recurrence, 
distal metastasis.
          Downsizing was defined as a reduction in the size of tumour after chemoradiotherapy as 
determined by physical examination. Downstaging was defined as decrease in TNM stage, as assessed 
after chemoradiotherapy in the surgically resected specimen.
         
Results
          
                                From September 2005 to April 2008, fifty five patients were enrolled in the study. 
Seven patients dropped out during various phases of treatment, three patients during radiotherapy after 
three weeks of treatment when their rectal bleed stopped, four patients after completion of 
chemoradiotherapy. Forty eight patients underwent surgery post chemoradiotherapy. Their 
demographic characters are presented below.
Age Mean     39.58 yrs
Range    24-61 yrs
Sex Male   26 (54.16%)
Female   22 (45.84%)
AGE
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  Sex Distribution
26
22 Male
Female
Distance from anal verge  No ( % ) 
0-4 cm 32 (66.6 % )
4-8 cm                                      15 ( 31.32 %)
8-12 cm       1 (2.08 % )
                         Patients age ranged from 24-61 yrs, mean age being 39.58 years. Twenty six were 
males and 22 were females. Most of the tumours extended into anal canal (66.6 %). Fifteen patients had 
tumours involving lower rectum and one had tumour involving middle rectum.
Tumour Characteristics
Clinical Stage of Tumour No ( % )
Stage 1 ( T1,T 2, N0,M0 ) 0
Stage 2 A ( T3, N0, M0 ) 4 (8.33 %)
Stage 2 B ( T4, N0, M0 ) 1(2.08 %)
Stage 3 A ( T1, T2, N1, M0 ) 0
Stage 3 B ( T3, T4, N1, M0 ) 36 (75 %)
Stage 3 C ( any T, N2, M0 ) 7 (14.58 %)
Stage 4 (any T, any N, M 1) 0
Pre operative Histology No ( % )
Well Differentiated 23 ( 48  % )
Moderately Differentiated 19 ( 39.5 % )
Poorly Differentiated 6  ( 12.5 % )
                        Thirty six patients had stage 3 B disease and seven had stage 3 C disease. Endorectal 
ultrasound was possible only in sixty percent of patients (twenty nine). Forty eight percent of patients 
had well differentiated carcinoma and thirty nine percent had moderately differentiated tumours. The 
interval from chemo radiotherapy to surgery ranged from six to nine weeks. The surgeries performed 
ranged from anterior resection, with concomitant hysterectomy to abdominoperineal excision of 
rectum.
Surgical Data
Interval to Surgery in weeks
6
7
8
9
No of cases
24
17
6
1
Type of surgery No of cases
Anterior Resection
Anterior Resection with adjacent organ 
resection
Abdominoperineal resection 
Colostomy alone
13
2
32
1
               Distance from anal verge
0
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0
5
10
15
20
25
30
35
40
45
AR APER
INTENDED
DONE
  Twenty four patients underwent surgery at six weeks after chemoradiotherapy, seventeen 
patients seven weeks post chemoradiotherapy. In one patient, surgery was done at nine weeks as she 
had developed respiratory infection and surgery was delayed. Thirteen patients underwent anterior 
resection, two patients had uterine involvement and underwent concomitant hysterectomy and posterior 
vaginectomy. Thirty two patients underwent abdominoperineal resection .In one patient growth had 
extended up to pelvic side wall, was inoperable and a palliative sigmoid colostomy was done. 
Complications
Peroperative complications
            Bleeding 1 (2.08 % )
Post operative complications
           Abdominal wound infection
           Perineal wound infection
           Intraabdominal abscess 
           Urinary retention
          
8 (16.66 % )
5  (10.41 % )
1 (2.08 %)
1 (2.08 % )
1 (2.08 %)
Chemoradiotherapy toxicity
           Mild-Skin irritation & 
discoloration
                     Vomiting  
                     Diarrrhoea
           Severe – Anaemia
8 (16.66 % )
5 (10.41 % )
2 (4.16 % )
1 (2.08 % )
1 (2.08 % ) 
               One patient developed intraoperative bleeding due to injury to sacral plexus. It was controlled 
by placing a tacker in the sacral ostia. Minor complications occurred in eight  patients, five developed 
abdominal wound infection which was treated conservatively. One patient developed perineal wound 
gaping treated with regular dressings. One patient developed abscess in left iliac fossa which was 
drained under ultrasonic guidance. One patient developed urinary retention in the postoperative period, 
was treated with continous bladder drainage for 3 months followed by intermittent self catheterization 
for another month. She had complete recovery 4 months after surgery. 
           One patient developed anaemia requiring blood transfusion after the second dose of 
chemotherapy in the fifth week. Minor complications like skin irritation occurred in five patients, 
vomiting in two, diarrrhoea in one.
Results of Surgery
Downsizing of Tumour 46/48       p (<0.0001 )
Downstaging of Tumour 39/48       p ( <0.0001 )
Followup Period 6 months-2 yr 2 months (median- 9 months)
Local reccurence Nil
Distant metastasis 1/48  (2.08 %)     
 
    
Forty six of forty eight patients had responded well to neoadjuvant chemoradiotherapy with 
downsizing of tumour .(p value <0.0001 ). Downstaging occurred in thirty nine (p< 0.0001). The 
follow up period ranged  from six months to twenty six months ,with the median follow up period 
being nine months. No patient developed local recurrence. Liver metastasis occurred in one patient who 
had disease progression up to pelvic side walls and was hence inoperable. 
APER intended Sphincter saving procedure done
42 10/42  (23.8 %)
                       
                  Of forty two patients for whom APER was planned, a sphincter conservation surgery was 
possible in ten of them after neoadjuvant chemoradiotherapy. Before neoadjuvant chemoradiotherapy 
only six anterior resections were planned. After it, fifteen anterior resections were done.
Anterior resections intended Anterior resections done
6(12.5 % ) 15   (31.5 % )                       P = 0.001
                    Neoadjuvant chemoradiotherapy increased sphincter conservation from 12.5% to 31.5%.
Post operative TNM staging
Stage 1  ( T1, T2, N0, M0 ) 11 ( 22.91 % )
Stage 2 A  ( T3, N0, M0 ) 16  (33.33% )
Stage 2 B ( T4, N0, M0 ) 0
Stage 3 A ( T1, T2, N1, M0 ) 3 ( 6.25 %)
Stage 3 B ( T3, T4, N1, M0 ) 17 (35.42 %)
Stage 3 C ( any T, N2, M0 ) 1 (2.08 % ) 
Stage 4 ( any T, any N, M1 ) 0
Patient compliance
                Forty eight out of fifty five patients had a complete course of chemoradiotherapy followed by 
surgery  (87.27 % ).
Statistical Analysis
Statistical analysis was done using SPSS version 11.4 software and SAF software. The 
categorical variables were tested using test of one proportion and chi square test. A p value of less than 
0.05 was considered statistically significant.
 Discussion
            Significant advances have been made in the study of colorectal cancer over the last few years. A 
more thorough understanding of the molecular basis for this disease, coupled with the development of 
new therapeutic approaches, has dramatically altered the way in which patients are managed. New 
strategies for screening and for the detection of recurrent disease have also impacted the way 
physicians approach the workup and disease staging of their patients. 
Preoperative Chemoradiotherapy
                          In resectable rectal cancers the rationale for giving preoperative chemoradiotherapy is not only  
to improve the survival but also on the potential advantage of delivering both the agents preoperatively. 
These advantages include improved  compliance with the chemotherapy regimen if it is given before a 
major surgery as well  as downstaging which may enhance the rate of curative surgery and permit 
sphincter preservation in low lying rectal  tumours. In addition,  because the tumour oxygenation is 
better if given preoperatively, irradiation is more effective when given preoperatively. 
The  rates  of  sphincter  conservation  surgery  is  also  doubled  after  preoperative 
chemoradiotherapy. Postponing the surgery to six weeks later helps shrinkage of tumour and recovery 
of  tissues  after  treatment.  The  addition  of  5-FU  to  preoperative  radiotherapy  produces  a  higher 
pathological complete response (pCR) rate over radiotherapy alone13, and there is evidence for better 
locoregional control, but no improvement in disease-free survival (DFS) or overall survival has been 
demonstrated. Distant metastases occur in at least 30% of cases.
             Nevertheless,  because  of  the better  pCR and locoregional  control  rates,  5-FU–based 
preoperative chemoradiotherapy followed by total mesorectal excision has become the standard of care 
in patients with locally advanced rectal cancer.
            More  recently,  oxaliplatin  and  irinotecan  have  been  explored  within  a  chemoradiotherapy 
schedule to increase tumor shrinkage prior to surgery and potentially mirror the success of oxaliplatin 
in dealing with distant micrometastases in colon cancer. Current chemoradiotherapy schedules have 
been  empirically  developed.  There  is  no  widely accepted  optimal  schedule,  sequence,  and  timing, 
either in terms of the drugs or RT dose.
               Radical pelvic RT at doses of 55–60 Gy is associated with high levels of normal tissue 
damage, including small bowel injury, rectal bleeding, impaired sphincter function, vaginal stenosis, 
nerve dysfunction, and sacral fractures. Lower radiotherapy  doses, 40–50 Gy in 1.8- to 2.0-Gy 
fractions, are associated with a good tumor response and with more acceptable levels of late morbidity. 
These doses have become established as a standard. 
Downsizing of tumour
                                             
Study Downsizing   p value 
Polish Trial 13  2004 Present p <0.001
German Rectal Cancer 
Study group12  2004
Present p < 0.001 
EORTC  trial  2292117 Present p <0.001
2005
This study Present  95.8 %  p < 0.0001
       
      
    Neoadjuvant chemoradiotherapy helps significant downsizing of tumour as it causes tumour 
shrinkage. In this study downsizing occurred in forty six of forty 
Post RT fibrosis in APER Specimen
eight patients (95.8 % ), p < 0.0001. This is in accordance with other studies which have shown similar 
significant regression of the tumour after chemoradiotherapy.  In one patient he had a poorly 
differentiated adenocarcinoma  infilterating the bladder anteriorly. An anterior pelvic exenteration was 
planned for this patient after preoperative chemoradiotherapy .But the tumour had extended to the 
pelvic side walls following treatment and was inoperable and a palliative colostomy was done. He 
developed liver metastasis in seven months. Another patient had tumour progression into the anal canal 
necessitating an abdominoperineal excision of rectum. Downsizing is a indicator of  good response to 
preoperative chemoradiotherapy. This is concurrence with the results of Polish trial 13  the tumour was 
1.9 cm smaller in patients after chemoradiotherapy.
Downstaging of tumour
                                                              
Study Down Staging  Percentage of patients 
downstaged
Rich et al 20, 1995 Present 64  % p <0 .01
German  Rectal Cancer 
Group Trial 12 2004
Present 62 % p < 0.001
EORTC Trial 22921 17 
2005
Present 52 % p < 0.001
Chung Wah Lam et al 4 
2005
Present 69  % p <0.01 %
This study Present 83.3 %  p < 0.0001
 
      After preoperative chemoradiotherapy, postoperative histopathology shows downgrading of the 
tumour. In this study thirty nine of forty eight patients (83.3%) showed downstaging (p <0.0001). A 
good pathological response is a good prognostic indicator, with patients having a good response having 
less incidence of local recurrence and improved overall survival. Chung Wah Lam et al 4  in 2005 has 
shown that 69 % of his patients had decreased tumour stages after chemoradiotherapy. 
Preoperative TNM Staging Vs Post operative TNM Staging
This Study
  In this study preoperatively around 75 % of the tumours were in stage 3 B. Post operative 
Stage Preoperative TNM Postoperative TNM
Stage 1 ( T1,2, N0, M0 ) 0 11 ( 22.91 % )
Stage 2 A( T3, N0, M0 ) 4  (8.33% ) 16  (33.33% )
Stage 2 B ( T4, N0, M0 ) 1 ( 2.08 % ) 0
Stage 3A ( T1, T2, N1, M0) 0 3 ( 6.25 %)
Stage 3B ( T3, T4, N1, M0) 36 ( 75 % ) 17 (35.42 %)
Stage 3 C ( any T, N2, M0 ) 7  (14.58 % ) 1 (2.08 % ) 
Stage 4 (any T, any N, M1) 0 0
histopathology showed a significant shift towards lower stages stage 2A in 33.33% and 22.91 % in 
stage 1. The decrease from 75 % to 35 % shows clearly the benefit of preoperative chemoradiotherapy. 
Due to the tumoricidal effect of chemoradiotherapy  the lymph node positivity was reduced from 89.5 
% to 43.75 %.
Effect of time interval on surgery and downstaging
           When the optimum time interval between radiotherapy and surgery was  analysed non 
randomized retrospective data led to the hypothesis that a long time interval  between radiotherapy and 
surgery led to sphincter preservation because  of tumour downstaging. Francois et al 21  in 1999, 
conducted a randomized trial to compare short interval outcome with long interval of 6-8 weeks. A 
long interval between preoperative radiotherapy and surgery was associated with a significantly better 
clinical tumor response (53.1% in the SI groupv 71.7% in the LI group, P.007) and pathologic 
downstaging (10.3% in the SI group v 26% in the LI group, P .005).  At a median follow-up of 33 
months, there were no differences in morbidity, local relapse, and short-term survival between the two 
groups.
                 
Sphincter-preserving surgery was performed in 76% of cases in the LI group versus 68% in the 
SI group (p < 0.27).He concluded that a long interval between preoperative irradiation and surgery 
provides increased tumor downstaging with no detrimental effect on toxicity and early clinical results. 
When sphincter preservation is questionable, a long interval may increase the chance of a successful 
sphincter-saving surgery.
                   The ideal time interval is 6 weeks following surgery when there is an optimal tumour 
response and further delay does not enhance the effect of radiotherapy. When fibrosis sets in, dissection 
also  becomes  technically  difficult  with  increased  incidence  of  complications  like  intra  abdominal 
sepsis, increased bleeding etc. In this study, the interval ranged from 6 to nine weeks, median being six 
weeks.
Stapled Anterior Resection
Stapled Anterior Resection
Doughnuts after Anterior Resection
Sphincter Saving Procedures after neoadjuvant chemoradiotherapy
Study Sphincter saving    Percentage 
Rich et al 20 1995 Present 66.6  %
NSABP Trial 14 1997 Present 50  %
Polish Trial 13 2004 Present 58  %
German  Rectal Cancer 
Group Trial 12 2004
Present 39  %
Chung Wah Lam et al 4 
2005
Present 82  %
This study Present 31.5 %
     One of the advantages of preoperative chemoradiotherapy is that tumour downsizing helps sphincter 
saving procedures possible. The incidence of sphincter saving procedures range from 39 % up to 82 %. 
In this study, preoperatively only six patients were planned for an anterior resection. After neoadjuvant 
therapy, anterior resection was possible in fifteen patients, sphincter conservation rates were increased 
from 12.5 % to 31.5 % (p < 0.001) .The lower number of sphincter saving procedures is due to the fact 
that most of the tumours (66.6 % ) had already exrended into the anal canal, hence necessitating 
abdominoperineal excision of rectum.
Distal Resection Margin after Neoadjuvant chemoradiotherapy
               Despite the increasing use of sphincter preservation for rectal cancers, nearly 50% of patients 
still undergo abdominoperineal excision of rectum. In many circumstances, abdominoperineal excision 
of rectum is performed out of concern for adequate distal margins despite mounting evidence that more 
limited distal margins may be appropriate. For low lying rectal tumours doing an abdominoperineal 
excision does not increase the radicality of the procedure or improve survival Although distal margins 
as great as 5 cm were advocated in the past, Paty et al found no increase in pelvic recurrence when the 
distal margin was <2 cm compared with > 2 cm.More recent data suggest that 1 cm distal margins are 
adequate 2,22.
               A number of clinical pathological studies 2,22  that examined distal intramural spread suggest 
that smaller distal margins, even 1 cm, may be adequate in the majority of cases. This is supported by 
pathological evidence that distal intramural spread rarely exceeds 1. When significant distal spread does 
occur, long­term survival is affected adversely, despite treatment with abdominoperineal excision of 
rectum. The presence of distal spread is associated with decreased survival primarily due to distant 
disease recurrence. Although mounting evidence supports the use of 1­cm distal margins in rectal 
cancer resections, the use of centimeter and subcentimeter margins is controversial.
             Jose G Guillem  et al 23 on prospective pathological analysis of whole mount sections of rectal 
cancer following combined modality therapy in 109 patients has shown that intramural extension 
occurred only in 1.8 % patients (<0.95 cm ). Hence he concluded 1 cm margins are sufficient after 
preoperative chemoradiotherapy and this increases the chances of sphincter preservation without 
increasing the chances of local recurrence.
        Preoperative chemoradiotherapy also reduces circumferential resection margin positivity. 
Circumferential resection margin positivity is as high as 25 % if no preoperative chemoradiotherapy is 
used. In this study a distal margin of one cm did not result in margin positivity in any of the 
postoperatively examined specimens.
Local Recurrence
      
                
 Local recurrence depends on multitude of factors like stage of the tumour. Tumours that are 
locally extensive are far more likely to recur than those that are mobile, no matter which type of 
procedure is performed. The frequency of local recurrence is significantly higher in patients who have 
circumferential involvement than those without involvement. Recurrence is also influenced by site of 
lesion in rectum, lower one third tumours have higher incidence than upper third tumours. Incomplete 
Study  Duration of follow 
up         
Local 
Recurrence 
Percentage
EORTC Trial 1 1984 7 years Present 15 %
Rich et al 20 1995 2 years,3 months Present 4 %
Polish Trial 13 2004 4 years Present 14.2 %
German  Rectal Cancer 
Group Trial 12 2004
4 years Present 6 %
EORTC Trial 22921 17 
2005
5.4 years Present 8 %
Chung Wah Lam et al 4 
2005
12.5 months Present 13.6 %
Jean Pierre Gerard et al 19 
FFCD 9203, 2006
81 months Present 8.1 %
This study 9 months Nil 0 %
removal of tumour is a very important cause for local recurrence
Stage of the disease, preoperative therapy used, surgical technique whether TME is used or not 
influences local recurrence. Local recurrence ranges from 5 .8 % as reported by Kapitjein et al 24  to 15 
%. This study during a follow up ranging from 6 months to twenty six months has had no evidence of 
local recurrence. This correlates well with the excellent response to chemoradiotherapy and an 
adequate TME as evidenced by downstaging and downsizing.       
           
                 The use of TME also must be considered as a contributing factor in reducing pelvic 
recurrences to as low as 5% to 8% in high­risk patients 2. Quirke et al. demonstrated that radial spread 
into the mesorectum is a common occurrence. Sharp dissection along the parietal pelvic fascia ensures 
resection of these small (5 mm) occult nodal metastases that otherwise might be left behind. Radial 
margins are a more important predictor of disease recurrence and survival than distal margins.
                  There is an increased risk of recurrence for patients who undergo have abdominoperineal 
excision of rectum as described previously and likely reflects the worse prognosis attributed to tumors 
of the low rectum compared with midrectal tumors. The location of the tumor may be a more important 
prognostic factor than the type of operation performed.
Toxicity of chemoradiotherapy
Study        Mild Toxicity (%)  Severe Toxicity(%)
German  Rectal Cancer 12  27
Group Trial 12 2004
EORTC Trial 22921 17 
2005
38.4  13.9
This study 16.66 2.08
           
                    About 16.6 % of patients developed toxicity of chemoradiotherapy. Skin irritation and 
discoloration was the most common toxicity encountered. It was totally reversed after few weeks. This 
is comparable with other studies showing a range of 11 % to 15 %. The EORTC 2292117 trial showed a 
very high toxicity of 38.4 %.  In this study no patient had a change in the chemoradiotherapy schedule 
due to toxicity.
Postoperative complications
                                      
Study    Complications(%)
German  Rectal Cancer Group Trial 12 
2004
36 
EORTC Trial 22921 17 2005 22.8
Jean Pierre Gerard et al 19   FFCD 9203, 
2006
20.9 
This study 16.66
              
  There   is   always   a   fear   that   neoadjuvant   chemoradiotherapy   increases   preoperative 
complications, delays wound healing, patients may need perineal flap cover to prevent post operative 
wound disruption. The postoperative complications in this study was 16.66 % only. Of  32  patients who 
underwent   only   on   abdominoperineal   excision   of   rectum   only   one   developed   perineal   wound 
complication which was successfully treated conservatively. So preoperative chemoradiotherapy can be 
given safely with good patient compliance, minimal side effects and less postoperative complications.
Effect on survival
  Most of the randomized controlled studies have not shown any significant survival benefit 
compared to preoperative radiotherapy alone. Jose G.Guilem et al 25 analysed the long term outcome 
following preoperative combined modality therapy and total mesorectal excision of locally advanced 
rectal cancer.  With a median follow-up of 44 months, the estimated 10-year overall survival was 58% 
and 10 year recurrence-free survival (RFS) was 62%. On  analysis, pathologic response  of greater than 
95%, lymphovascular invasion and/or perineural invasion (PNI), and positive lymph nodes were 
significantly associated with overall survival and disease free survival. Patients with a 95% pathologic 
response had a significantly improved overall survival (p < 0.003) and disease free survival (p < 
0.002).     
Rectal cancer recurrence may be delayed following preoperative chemoradiotherapy and TME 
and that surveillance of more than 5 years may be warranted. The treatment of locally advanced rectal 
cancer with preoperative chemoradiotherapy and radical rectal resection with TME currently provides 
the optimal treatment standard for a durable long-term oncologic outcome in properly selected patients 
CONCLUSION
             Neoadjuvant chemoradiotherapy given in operable locally advanced mid and low rectal cancers 
causes significant downsizing, downstaging of the tumour, increases the rate of sphincter conservation 
surgeries. The toxicity of chemoradiotherapy is minimal, patient compliance is good. The postoperative 
complications are not increased and it helps decrease the incidence of local recurrence .The effect on 
survival has to be determined on long term follow up only. Hence it is beneficial to administer it to 
patients with locally advanced operable mid and low rectal cancers. 
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Proforma
Name
Age
Sex
Distance of 
tumour 
from anal 
verge
ERUS;  Possible  /  Not possible
Findings ; 
Preoperative Histology :
CECT Abdomen & Pelvis ;
Colonoscopy :
Cystoscopy  :
X Ray Chest :
Clinical TNM:
Chemo radiotherapy compliance: Yes /  No
Toxicity of Chemo radiotherapy
 Acute
Diarrhoea
Dermatological
Hematological
Chronic
Time interval from Chemo radiotherapy to surgery :
Post Chemoradiotherapy Staging :
Downsizing : Yes /  No  / Increased in size
Type of surgery : AR / APER /  Hysterectomy / anterior exenteration / posterior    exenteration / 
inoperable
Use of protective ostomy : Yes / No
0-4 cm 4-8 cm 8-12 cm > 12 cm
Diarrhoea 
Small Bowel obstruction
Stricture at anastamotic site
Bladder dysfunction
Findings at surgery ;
Peroperative Complications ;
Difficulty in dissection :
Bleeding & blood loss :
Postoperative HPE ; Response complete  / partial  /  none
 TNM
Post operative Complications
Complication Yes No
Ileus
Wound infection
Intra abdominal abscess
Non healing perineum
Rectovaginal Fistula
Urinary tract infection
Urinary retention
ARDS
Aspiration
SI obstruction
Retrograde ejaculation
Ventral hernia
Length of hospital stay :
30 day mortality :
Follow up :
Period 3 months 6 months 9 months 12 months
Physical 
examination
Radiological 
investigations
Inference
Period 15 months 18 months 21 months 24 months
Physical 
examination
Radiological 
investigations
Inference

